Journal article
Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study
ML Montes, M Nelson, PM Girard, J Sasadeusz, A Horban, B Grinsztejn, N Zakharova, A Rivero, J Durant, E Ortega-Gonzalez, E Lathouwers, K Janssen, S Ouwerkerk-Mahadevan, J Witek, J González-García
Journal of Antimicrobial Chemotherapy | OXFORD UNIV PRESS | Published : 2016
DOI: 10.1093/jac/dkv323
Abstract
Objectives: INSIGHT (ClinicalTrials.gov NCT01513941) evaluated the efficacy, safety and pharmacokinetics of telaprevir-based therapy and specific antiretroviral agents in hepatitis C virus genotype 1 (HCV-1)/HIV-1-coinfected patients. Patients and methods: Open-label, Phase IIIb, multicentre study of telaprevir with pegylated-IFN (Peg-IFN)α2a and ribavirin in treatment-naive or -experienced HCV-1/HIV-1-coinfected patients on stable HIV HAART comprising efavirenz, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, etravirine or rilpivirine with two nucleos(t)ide analogues. Patients received 750 mg telaprevir (1125 mg, if on efavirenz) every 8 h plus 180 μg/week Peg-IFNα2a and 800 mg/day ..
View full abstractGrants
Funding Acknowledgements
This work was supported by Janssen Pharmaceuticals. In addition, the editorial support (see below) was funded by Janssen Pharmaceuticals.